Vorasidenib
Voranigo (vorasidenib) is a small molecule pharmaceutical. Vorasidenib was first approved as Voranigo on 2024-08-06. It is used to treat oligodendroglioma in the USA. It is known to target isocitrate dehydrogenase [NADP], mitochondrial and isocitrate dehydrogenase [NADP] cytoplasmic.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Voranigo
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| voranigo | New Drug Application | 2025-04-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| oligodendroglioma | EFO_0000631 | D009837 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioma | D005910 | EFO_0000520 | — | 1 | — | 1 | — | 1 | 3 |
| Recurrence | D012008 | — | — | — | — | 1 | — | 1 | 2 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Germ cell and embryonal neoplasms | D009373 | — | — | — | — | — | — | 1 | 1 |
| Neoplasms by histologic type | D009370 | — | — | — | — | — | — | 1 | 1 |
| Glandular and epithelial neoplasms | D009375 | — | — | — | — | — | — | 1 | 1 |
| Nerve tissue neoplasms | D009380 | — | — | — | — | — | — | 1 | 1 |
| Primitive neuroectodermal tumors | D018242 | — | — | — | — | — | — | 1 | 1 |
| Neuroepithelial neoplasms | D018302 | — | — | — | — | — | — | 1 | 1 |
| Neuroectodermal tumors | D017599 | — | — | — | — | — | — | 1 | 1 |
| Disease attributes | D020969 | — | — | — | — | — | — | 1 | 1 |
| Pathologic processes | D010335 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vorasidenib |
| INN | vorasidenib |
| Description | Vorasidenib is an experimental anti-cancer medication for the treatment of low-grade glioma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2), which are mutated in several forms of cancer. In a phase-III-trial, it was shown to prolong progression-free survival in patients with IDH1- or IDH2-mutant low-grade glioma.
|
| Classification | Small molecule |
| Drug class | mutated isocitrate dehydrogenase (IDH) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 1644545-52-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4279047 |
| ChEBI ID | — |
| PubChem CID | 117817422 |
| DrugBank | DB17097 |
| UNII ID | 789Q85GA8P (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
IDH2
IDH2
IDH1
IDH1
Organism
Homo sapiens
Gene name
IDH2
Gene synonyms
NCBI Gene ID
Protein name
isocitrate dehydrogenase [NADP], mitochondrial
Protein synonyms
ICD-M, IDP, isocitrate dehydrogenase (NADP(+)) 2, mitochondrial, isocitrate dehydrogenase 2 (NADP+), mitochondrial, NADP(+)-specific ICDH, Oxalosuccinate decarboxylase
Uniprot ID
Mouse ortholog
Idh2 (269951)
isocitrate dehydrogenase [NADP], mitochondrial (Q9EQK1)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 595 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
196 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use